MX355624B - Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos. - Google Patents
Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.Info
- Publication number
- MX355624B MX355624B MX2014007359A MX2014007359A MX355624B MX 355624 B MX355624 B MX 355624B MX 2014007359 A MX2014007359 A MX 2014007359A MX 2014007359 A MX2014007359 A MX 2014007359A MX 355624 B MX355624 B MX 355624B
- Authority
- MX
- Mexico
- Prior art keywords
- vectors containing
- clones
- signal sequence
- polya signal
- productivity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a transfecciones transitorias el uso del promotor alfa de factor 1 de elongación humano (con el intrón A) proporciona una productividad mejorada (en organización de LC-HC-SM), el uso de la secuencia de señal poliA de hormona del crecimiento bovina proporciona una productividad mejorada en comparación con el uso de la secuencia de señal poliA de SV40, la adición de hGT a la secuencia de señal poliA de bGH resulta en una productividad aumentada en vectores que contienen el promotor hCMV y la organización de vector CL (3'-5')-HC-SM resulta en expresión mejorada. Para acumulados estables se reporta que acumulados generados con vectores que contienen el promotor a de hEF1 muestran una productividad mejorada en análisis por lotes, clones generados con los vectores que contienen el promotor hEF1a muestran un número reducido de clones poco productores, y los clones generados con vectores que contienen el promotor hEF1a muestran una mayor estabilidad de expresión de IgG. Para clones únicos se reporta que la organización del vector con la posición corriente abajo del marcador de selección (LC-HC-SM) tiene un efecto positivo sobre la productividad de clones únicos y que los clones generados con vectores que contienen la secuencia de señal poliA de bGH y hGT tienen las mayores productividades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11195361 | 2011-12-22 | ||
PCT/EP2012/076203 WO2013092743A2 (en) | 2011-12-22 | 2012-12-19 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014007359A MX2014007359A (es) | 2014-08-01 |
MX355624B true MX355624B (es) | 2018-04-25 |
Family
ID=47504950
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017012736A MX370481B (es) | 2011-12-22 | 2012-12-19 | Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos. |
MX2014007359A MX355624B (es) | 2011-12-22 | 2012-12-19 | Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017012736A MX370481B (es) | 2011-12-22 | 2012-12-19 | Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20160208284A1 (es) |
EP (2) | EP2794651B1 (es) |
JP (4) | JP6096802B2 (es) |
KR (4) | KR102229491B1 (es) |
CN (4) | CN113881702A (es) |
BR (1) | BR112014014239B1 (es) |
CA (2) | CA3149402A1 (es) |
ES (1) | ES2930215T3 (es) |
HK (1) | HK1200848A1 (es) |
HR (1) | HRP20221383T1 (es) |
MX (2) | MX370481B (es) |
PL (1) | PL2794651T3 (es) |
RU (2) | RU2756910C2 (es) |
SG (3) | SG10201700169PA (es) |
WO (1) | WO2013092743A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046975B2 (en) | 2013-10-07 | 2021-06-29 | Prestige Biopharma Pte. Ltd. | Bicistronic expression vector for antibody expression and method for producing antibody using same |
CN105255867A (zh) * | 2015-10-19 | 2016-01-20 | 北京益生合生物科技有限公司 | 一种防止启动子在传代培养中逐渐灭活的基因序列及其应用 |
ES2823173T3 (es) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Promotor híbrido y usos del mismo |
US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
EP3528852A4 (en) | 2016-10-20 | 2020-06-03 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY'S DISEASE |
CN110636859B (zh) * | 2017-05-19 | 2024-05-03 | 科学与工业研究委员会 | 用于产生重折叠的重组人源化兰尼单抗的方法 |
JP7081139B2 (ja) * | 2017-12-20 | 2022-06-07 | 東ソー株式会社 | 新規プロモーターおよびそれを含む発現ベクター |
AU2019342866A1 (en) * | 2018-09-20 | 2021-05-20 | Sanofi | Intron-based universal cloning methods and compositions |
KR102559149B1 (ko) * | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
CN117043194A (zh) | 2021-01-29 | 2023-11-10 | 默沙东有限责任公司 | 程序性死亡受体1(pd-1)抗体的组合物以及获得所述组合物的方法 |
KR102640929B1 (ko) | 2023-06-02 | 2024-02-27 | (주) 멥스젠 | 미세생체조직시스템 형성 장치 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規dnaならびにそれを含有する発現プラスミド |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
RU2201449C2 (ru) * | 1994-10-14 | 2003-03-27 | Сембайозис Дженетикс Инк. | Слитый полипептид, способный к целенаправленному переносу к масляному телу, химерная днк-контрукция, экспрессирующая кассета |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
DK2857516T3 (en) | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
EA007905B1 (ru) * | 2001-11-16 | 2007-02-27 | Байоджен Айдек Инк. | Полицистронная экспрессия антител |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
DE60336548D1 (de) | 2002-04-09 | 2011-05-12 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
SI2289936T1 (sl) | 2002-12-16 | 2017-10-30 | Genentech, Inc. | Imunoglobulinske variante in njihove uporabe |
CN100383244C (zh) * | 2003-01-07 | 2008-04-23 | 西福根有限公司 | 用于生产重组多克隆蛋白质的方法 |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2005035586A1 (ja) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | 融合蛋白質組成物 |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
LT2380911T (lt) | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
CN101001953B (zh) * | 2004-06-17 | 2013-03-13 | 惠氏公司 | 具有三个完整转录单元的质粒和用于诱导hiv免疫反应的免疫原性组合物 |
CN101292036B (zh) * | 2005-10-21 | 2016-04-13 | 弗·哈夫曼-拉罗切有限公司 | 用于重组表达多肽的方法 |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
WO2008077545A1 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Selection method |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
NZ580378A (en) * | 2007-03-30 | 2012-11-30 | Abbott Lab | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells |
EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
KR101183764B1 (ko) * | 2007-06-29 | 2012-09-17 | 에프. 호프만-라 로슈 아게 | 프로모터 |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
JP5788796B2 (ja) * | 2008-08-28 | 2015-10-07 | ノバルティス アーゲー | 終止コドンのリードスルーによるポリペプチドアイソフォームの細胞表面提示 |
GB0903207D0 (en) * | 2009-02-25 | 2009-04-08 | Ucb Pharma Sa | Method for expressing multimeric proteins |
JP5501439B2 (ja) | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | 完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体 |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
EP2435473B1 (en) | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
-
2012
- 2012-12-19 EP EP12810245.6A patent/EP2794651B1/en active Active
- 2012-12-19 ES ES12810245T patent/ES2930215T3/es active Active
- 2012-12-19 RU RU2017140661A patent/RU2756910C2/ru active
- 2012-12-19 BR BR112014014239-4A patent/BR112014014239B1/pt active IP Right Grant
- 2012-12-19 US US14/367,680 patent/US20160208284A1/en not_active Abandoned
- 2012-12-19 CN CN202111170578.8A patent/CN113881702A/zh active Pending
- 2012-12-19 CN CN201710324350.7A patent/CN107119073A/zh active Pending
- 2012-12-19 SG SG10201700169PA patent/SG10201700169PA/en unknown
- 2012-12-19 SG SG10201900915WA patent/SG10201900915WA/en unknown
- 2012-12-19 CN CN201280062793.9A patent/CN104011075B/zh active Active
- 2012-12-19 CA CA3149402A patent/CA3149402A1/en active Pending
- 2012-12-19 HR HRP20221383TT patent/HRP20221383T1/hr unknown
- 2012-12-19 PL PL12810245.6T patent/PL2794651T3/pl unknown
- 2012-12-19 KR KR1020207007391A patent/KR102229491B1/ko active IP Right Grant
- 2012-12-19 JP JP2014547983A patent/JP6096802B2/ja active Active
- 2012-12-19 WO PCT/EP2012/076203 patent/WO2013092743A2/en active Application Filing
- 2012-12-19 RU RU2014129727A patent/RU2639519C2/ru active
- 2012-12-19 CA CA2854249A patent/CA2854249C/en active Active
- 2012-12-19 CN CN202111171021.6A patent/CN113896787A/zh active Pending
- 2012-12-19 KR KR1020197034166A patent/KR102166824B1/ko active IP Right Grant
- 2012-12-19 MX MX2017012736A patent/MX370481B/es unknown
- 2012-12-19 EP EP18157484.9A patent/EP3354660A1/en active Pending
- 2012-12-19 KR KR1020217007341A patent/KR102285184B1/ko active IP Right Grant
- 2012-12-19 MX MX2014007359A patent/MX355624B/es active IP Right Grant
- 2012-12-19 SG SG11201403443WA patent/SG11201403443WA/en unknown
- 2012-12-19 KR KR1020147016825A patent/KR102048556B1/ko active IP Right Grant
-
2015
- 2015-02-04 HK HK15101213.2A patent/HK1200848A1/xx unknown
-
2017
- 2017-02-16 JP JP2017026502A patent/JP6417436B2/ja active Active
-
2018
- 2018-10-05 JP JP2018189605A patent/JP2019030311A/ja active Pending
-
2019
- 2019-12-09 JP JP2019221805A patent/JP7096806B2/ja active Active
-
2020
- 2020-07-06 US US16/921,194 patent/US20210024952A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX355624B (es) | Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos. | |
FI3536797T3 (fi) | Siirtogeenin tehostettu ilmentäminen ja prosessointi | |
MX2017007634A (es) | Métodos para producir polipéptidos modificados por ctp de acción prolongada. | |
RU2014148136A (ru) | Композиции т-клеток с недостаточностью рецепторов т-клеток | |
WO2015042557A4 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
RU2013143303A (ru) | FcγRIIb-СПЕЦИФИЧНОЕ Fc-АНТИТЕЛО | |
MX364690B (es) | Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero. | |
RU2015112607A (ru) | Генетически модифицированные, не принадлежащие к человеческому роду животные и способ их использования | |
MX2015012361A (es) | Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes. | |
SG10201901417UA (en) | Production of proteins in glutamine-free cell culture media | |
CA2877521C (en) | Cells for producing recombinant iduronate-2-sulfatase | |
MX370861B (es) | Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la producción de factor de crecimiento del nervio beta. | |
HRP20170468T1 (hr) | Bispecifična protutijela protiv baff i protiv il-17 | |
HRP20200744T1 (hr) | Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida | |
MX371007B (es) | Vectores de expresión que comprenden un promotor de citomegalovirus quimérico y secuencias mejoradoras. | |
MY161552A (en) | A polynucleotide and polypeptide sequence and methods thereof | |
NZ603196A (en) | Methods of use of soluble cd24 for therapy of rheumatoid arthritis | |
MX2019003256A (es) | Vectores basados en el virus de la tristeza de los citricos para la expresion de gen/es ajenos. | |
CN104974226B (zh) | 一种用于蛋白质表达的信号肽 | |
WO2013032999A3 (en) | Polydnavirus vectors | |
MX2013011355A (es) | Metodo de produccion de polipeptido recombinante. | |
MX350668B (es) | Gen sintetico para expresion de schistosoma mansoni-14 en pichia pastoris, procedimientos de produccion de schistosoma mansoni-14 y su uso como vacuna y medio de diagnostico. | |
MX2015013842A (es) | Metodos y constructos para expresar proteinas biologicamente activas en celulas de mamifero. | |
HRP20110138T1 (hr) | Kultura staničnog medija bez seruma za stanice sisavaca | |
SG194473A1 (en) | EXPRESSION SYSTEM WITH SAR ELEMENT FROM IFNa2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |